Prevención de fracturas y brechas en el tratamiento, en los debates del 9º ARC en Osteoporosis
23/02/2019
El Annual Meeting de la AAOS, incluido en el programa de ARC en Osteoporosis 2019
26/03/2019

El congreso ASBMR, la estrella de nuevo en las sesiones de trabajo de ARC en Osteporosis 2019

La ASBMR (American Society for Bone and Mineral Research) celebró su ‘Annual Meeting’ de 2018 en el Palais des Congrès de Montréal, Quebec (Canadá), del 28 al 1 de octubre. La relevancia de este congreso se muestra en el elevado número de abstracts totales, que en la pasada edición ascendieron a 1.395. Todos ellos están ya disponibles online, en el área ‘Abstracts’ del Education Resource Center de la web de la ASBMR, en este enlace.

El resto de información relevante relacionada con el congreso –Webcasts y Highlights- se encuentra también en la página web de la ASBMR, en este otro enlace, aunque en este caso para acceder es necesario haberse registrado en la web.

El congreso ASBMR es el que mayor peso tiene dentro de cada edición de ARC en Osteoporosis, como podemos ver en la extensa lista de contenidos revisados de dicho evento a lo largo de las dos jornadas de trabajo:

ASBMR/ECTS Symposium: Speaking From The Gut: Bone And The Microbiome.

  • Microbiome, IGF-1 and Bone Formation.
  • Bone Strength and the Microbiome.
  • Osteomicrobiology

ASBMR/ECTS CLINICAL DEBATE: TREATMENT FOR OSTEOPOROSIS IS ASSOCIATED WITH IMPROVED MORTALITY

  • For the Motion: Roland Chapurlat. E. Herriot Hospital, France.
  • Against the Motion: Steven Cumming.

The Athlete’s Skeleton: Going the Distance

Stress Fractures in Athletes, Female Athlete Triad, Limiting Activity in Patients with Metabolic Bone Disorders.

SYMPOSIUM: SENESCENCE AND AGING BONE

  • Senescence-Associated Intrinsic Mechanisms of Osteoblast Dysfunctions.
  • Age-related Stromal Changes Drive Increased Bone Metastasis.
  • Therapeutic Opportunities to Target Senescence to Prevent Age-related Bone Loss.

ASBMR Secondary Fracture Prevention Initiative.

[ASBMR 1153]: Burosumab Improved Serum Phosphorus, Osteomalacia, Mobility, and Fatigue in the 48-Week, Phase 2 Study in Adults with Tumor-induced Osteomalacia Syndrome.

[ASBMR 1008]: Clinical features of 35 patients with 172 spontaneous vertebral fractures after denosumab discontinuation: a single center observational study.

[ASBMR 1074]: T-score as an Indicator of Fracture Risk on Therapy: Evidence From Romosozumab vs Alendronate Treatment in the ARCH Trial.

[ASBMR 1060]: Effect of Dual-Task Functional Power and Mobility Training: on Falls and Physical Function in Older People Living in Retirement Villages: A Cluster Randomised Controlled Trial.

[ASBMR18 FRI-0910]: Teriparatide Accelerates Proximal Humerus Fracture Consolidation – The Terafrap Study.

[ASBMR # 1061]: Skeletal Benefit/risk of Long-term Denosumab Therapy: A Virtual Twin Analysis of Fractures Prevented To Skeletal Safety Events Observed.

[ASBMR # FRI 0909]: A Pooled Analysis of Fall Incidence from Placebo-controlled Trials of Denosumab.

[ASBMR # 1051]: RANK Ligand inhibitors improve muscle function and glucose Homeostasis.

[ASBMR # 1073]: Rapid and Large BMD Increases in Postmenopausal Women Treated With Combined High-Dose Teriparatide and Denosumab: The DATA-HD Randomized Controlled Trial.

[ASBMR # 1059]: Effect of Denosumab and High-Dose Teriparatide on Peripheral Bone Mineral Density and Microarchitecture.

[ASBMR SAT-0505]: Beneficial effects of Denosumab on bone loss and bone erosion from results of long-term treatment in the phase 3, DESIRABLE study in patients with rheumatoid arthrtis (RA) on background cs DMARDs.

[ASBMR 1051]: Sympatetic Outflow Regulates Bone Metabolism in Humans: Evidence from Cellular, Epidemiological, and Direct Interventional Studies.

[ASBMR LB MON – 1213]: The effect of screening of high fracture risk and subsequent treatment on osteoporotic fractures: a systematic review and metaanalysis.

[ASBMR FRI-0745]: Secular trends in the initiation of therapy in secondary fracture prevention: widening treatment gaps in Denmark and Spain.

[ASBMR: 1058]: Change in Bone Turnover as a Surrogate for Fracture Outcomes: A Novel Individual level Analysis of Pooled Anti-resorptive Trials.

[ASBMR 1070]: Change in BMD as a Surrogate for Fracture Risk Reduction in Osteoporosis Trials: Results from Pooled, Individual-level Patient Data.

[ASBMR 1072]: VK5211, a Novel Selective Androgen Receptor Modulator (SARM), Significantly Improves Lean Body Mass in Hip Fracture Patients: Results of a 12 Week Phase 2 Trial.

[ASBMR: 1005]: Do Drug Holidays Reduce Atypical Femur Fracture Risk?

[ASBMR: 1007]: Bisphosphonate Use and Risk of AFF Varies by Pre-treatment BMD Level.

[ASBMR: FRI-0740] (Young Investigator Award): Risk Factors for Atypical Femur Fractures in a Large, Prospective Cohort Study: A Multivariable Analysis. From the Southern California Osteoporosis Cohort Study (SOCS). USFC & Kaiser Permanente.

 

ASBMR en la red

La ASBMR tiene una gran presencia en las redes sociales. En su página de facebook se publican noticias de interés y abstracts de artículos aceptados para publicación en el JBMR. En cuanto a Twitter, su cuenta es @ASBMR y para quienes quieran ver sus noticias en Linkedin, lo pueden hacer siguiendo su página.

 

ASBMR 2019

El ‘Annual Meeting’ de 2019 se celebrará del 20 al 23 de septiembre en ‘The Orange County Convention Center’ de Orlando, Florida, USA. Para consultar información sobre dicha Reunión Anual hacer clic en esta dirección.

REGISTRO